The histological diagnosis was lymphocytic hypophysitis. Immunostains were positive for CD3 and CD20. Immunostains for acid-fast bacilli, PLAP and OCT3/4 were negative. The patient remains ...

Investment company RTW Investments has launched a new biotech company called Prolium Bioscience, to advance the development of ICP-B02, a CD20×CD3 bispecific antibody originating from China’s ...

The 61 st annual meeting of the American Society of Hematology (ASH) conducted in 2019 presented bi-specific antibodies that target CD20 on the surface of B cells and CD3 on the surface of T cells ...

In another Chinese newco out-licensing deal, Innocare Pharma Ltd. and Keymed Biosciences Co. Ltd. out-licensed their co-developed CD20×CD3 bispecific antibody (ICP-B02/CM355) to startup Prolium ...

The company will halt further development of imvotamab or CD20 x CD3 and IGM-2644 or CD38 x CD3, both IgM-based bispecific antibody T cell engagers, for autoimmune diseases. Imvotamab or CD20 x ...

ICP-B02 binds to CD20 on the tumor cells and CD3 on the T cells, redirects and activates T cells to eradicate tumor cells through T-cell Directed Cellular Cytotoxicity (TDCC), which has ...

His Tag CD20 CD0-H82E3 Biotinylated Human CD20 / MS4A1 Full Length Protein, His,Avitag™ (Nanodisc) (HEK293) CD133 CD3-H52H1 Human CD133 Full Length Protein, His Tag (Nanodisc) CD133 CD3-H82E6 ...

The firm’s product pipeline includes IGM-2323, which is a CD20 x CD3 bispecific IgM antibody designed to treat patients with B cell Non-Hodgkin's lymphoma and other B cell malignancies ...

Therapeutic monoclonal antibodies (mAbs) are used in chronic lymphocytic leukemia immunotherapies to target the receptor CD20 at the plasma membrane of immunological B cells. Although they have ...